Press Release: KCAS Bioanalytical and Biomarker Services Welcomes Director of Large Molecule and Biomarker Services
Kansas City, KS. – (August 2017) KCAS Bioanalytical and Biomarker Services, a leading functional service
contract research organization (CRO) is pleased to announce the expansion of their Large Molecule and
Biomarker services team. Mr. Frank Spriggs joins KCAS as Director of Large Molecule and Biomarker
Services.
Mr. Spriggs has more than 15 years involvement in Ligand Binding Assay (LBA) bioanalysis with a focus
on pharmacokinetics, biomarkers, immunogenicity and quality assurance. His breath of knowledge in
development and optimization of LBA methods will further strengthen KCAS’ development capability. “I
am delighted Frank Spriggs has joined the growing KCAS team. Frank’s ligand binding assay expertise
and product development experience positions KCAS to accelerate its growth and expansion of
capabilities to serve our client’s development needs.” stated John Bucksath, CEO.
Mr. Spriggs joins KCAS from AIT Bioscience where he oversaw the LBA department and their molecular
biology analytical techniques and services offered. Previously he worked for Pfizer and Amgen building
upon his skills in method development, validation, and analysis of protein therapeutics in pre-clinical
and clinical phases of drug development. He currently holds leadership roles within the Regualtory
Sciences section of American Association of Pharmaceutical Scientist (AAPS). Spriggs earned his BS in
Microbiology from Ohio University and an MS in Quality Assurance and Regulatory Affairs from Temple
University.
“I am excited to be joining KCAS. The investment being made in the large molecule services has
positioned KCAS to become the bioanalytical partner of choice in the ever expanding discipline of large
molecule drug development.” stated Frank Spriggs.
About KCAS
KCAS Bioanalytical & Biomarker Services is a contract laboratory with 36+ years of bioanalytical
expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity,
and biomarker analysis operating a variety of equipment platforms to service a wide range of
therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure of 14 years at
the company to provide clients of all sizes with expertise in robust assay development, validation, and
sample analysis under non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies.
Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 15
FDA inspections. Recently KCAS registered for Clinical Laboratory Improvement Amendments (CLIA)
certification. Learn more at: www.kcasbio.com
Contact: [email protected]